Dismounting the MDR horse

被引：35

作者：

Libby, Edward ^{[1
]}

Hromas, Robert ^{[1
]}

机构：

[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA

来源：

BLOOD | 2010年 / 116卷 / 20期

关键词：

ACUTE MYELOID-LEUKEMIA; RISK MYELODYSPLASTIC SYNDROME; RESISTANCE; TRIAL; CYCLOSPORINE; CYTARABINE; MODULATION; DIAGNOSIS; PSC-833; CANCER;

D O I：

10.1182/blood-2010-09-304311

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4037 / 4038

页数：4

共 9 条

[1] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 [J].

Baer, MR ;

George, SL ;

Dodge, RK ;

O'Loughlin, KL ;

Minderman, H ;

Caligiuri, MA ;

Anastasi, J ;

Powell, BL ;

Kolitz, JE ;

Schiffer, CA ;

Bloomfield, CD ;

Larson, RA .

BLOOD, 2002, 100 (04) :1224-1232

[2] The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial [J].

Burnett, Alan K. ;

Milligan, Donald ;

Goldstone, Anthony ;

Prentice, Archibald ;

McMullin, Mary-Frances ;

Dennis, Michael ;

Sellwood, Elizabeth ;

Pallis, Monica ;

Russell, Nigel ;

Hills, Robert K. ;

Wheatley, Keith .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (03) :318-332

[3]

CAMPOS L, 1992, BLOOD, V79, P473

[4] Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 [J].

Cripe, Larry D. ;

Uno, Hajime ;

Paietta, Elisabeth M. ;

Litzow, Mark R. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Luger, Selina ;

Tallman, Martin S. .

BLOOD, 2010, 116 (20) :4077-4085

[5] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) [J].

Greenberg, PL ;

Lee, SJ ;

Advani, R ;

Tallman, MS ;

Sikic, BI ;

Letendre, L ;

Dugan, K ;

Lum, B ;

Chin, DL ;

Dewald, G ;

Paietta, E ;

Bennett, JM ;

Rowe, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1078-1086

[6] Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study [J].

List, AF ;

Kopecky, KJ ;

Willman, CL ;

Head, DR ;

Persons, DL ;

Slovak, ML ;

Dorr, R ;

Karanes, C ;

Hynes, HE ;

Doroshow, JH ;

Shurafa, M ;

Appelbaum, FR .

BLOOD, 2001, 98 (12) :3212-3220

[7] The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis [J].

van der Holt, B ;

Löwenberg, B ;

Burnett, AK ;

Knauf, WU ;

Shepherd, J ;

Piccaluga, PP ;

Ossenkoppele, GJ ;

Verhoef, GEG ;

Ferrant, A ;

Crump, M ;

Selleslag, D ;

Theobald, M ;

Fey, MF ;

Vellenga, E ;

Dugan, M ;

Sonneveld, P .

BLOOD, 2005, 106 (08) :2646-2654

[8]

Yin JAL, 2001, BRIT J HAEMATOL, V113, P713

[9] Cancer Clinical Trials - A Chronic but Curable Crisis [J].

Young, Robert C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (04) :306-309

← 1 →